Epigenomics
Market Cap
€46.6m
Last Updated
2019/10/18 21:21 UTC
Data Sources
Company Financials +
Executive Summary
Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia.
Snowflake
Fundamentals
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Epigenomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.4%
ECX
1.3%
DE Biotechs
3.9%
DE Market
1 Year Return
-33.9%
ECX
1.7%
DE Biotechs
3.4%
DE Market
Return vs Industry: ECX underperformed the German Biotechs industry which returned 1.7% over the past year.
Return vs Market: ECX underperformed the German Market which returned 3.4% over the past year.
Shareholder returns
| ECX | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.4% | 1.3% | 3.9% |
| 30 Day | -11.0% | -5.0% | 2.1% |
| 90 Day | -28.3% | -4.5% | 3.7% |
| 1 Year | -33.9%-33.9% | 1.8%1.7% | 6.7%3.4% |
| 3 Year | -74.6%-76.0% | 69.2%67.5% | 18.9%8.6% |
| 5 Year | -61.3%-63.5% | 14.0%11.5% | 41.8%22.5% |
Price Volatility Vs. Market
How volatile is Epigenomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
What Kind Of Shareholders Own Epigenomics AG (ETR:ECX)?1 month ago | Simply Wall St
Does Epigenomics AG's (ETR:ECX) CEO Salary Compare Well With Others?2 months ago | Simply Wall St
Epigenomics AG (ETR:ECX): Is Breakeven Near?Valuation
Is Epigenomics undervalued compared to its fair value and its price relative to the market?
3.99x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate ECX's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate ECX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ECX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ECX is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate ECX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ECX is overvalued based on its PB Ratio (4x) compared to the DE Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Epigenomics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
56.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ECX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ECX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ECX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ECX's revenue (68.6% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: ECX's revenue (68.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if ECX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Epigenomics performed over the past 5 years?
-6.8%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: ECX is unprofitable, and losses have increased over the past 5 years at a rate of -6.8% per year.
Accelerating Growth: Unable to compare ECX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ECX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ECX has a negative Return on Equity (-122.48%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: ECX is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: ECX is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Epigenomics's financial position?
Financial Position Analysis
Short Term Liabilities: ECX's short term assets (€10.6M) exceeds its short term liabilities (€3.0M)
Long Term Liabilities: ECX's short term assets (10.6M) exceeds its long term liabilities (851.0K)
Debt to Equity History and Analysis
Debt Level: ECX is debt free.
Reducing Debt: ECX has no debt compared to 5 years ago when its debt to equity ratio was 44.4%.
Balance Sheet
Inventory Level: ECX has a low level of unsold assets or inventory.
Debt Coverage by Assets: ECX's debt is not covered by short term assets (assets are -4.7567019264287E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ECX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -0.9% each year
Next Steps
Dividend
What is Epigenomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate ECX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ECX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if ECX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ECX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ECX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of Epigenomics's salary, the management and board of directors tenure and is there insider trading?
2.5yrs
Average management tenure
CEO
Greg Hamilton (49yo)
3.3yrs
Tenure
€962,253
Compensation
Mr. Gregory Hamilton, also known as Greg, has been the Chief Executive Officer and Member of Executive Board at Epigenomics AG since July 1, 2016. Mr. Hamilton has over 20 years of management experience in ...
CEO Compensation Analysis
Compensation vs. Market: Greg's total compensation ($USD1.07M) is about average for companies of similar size in the German market ($USD218.00K).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
2.5yrs
Average Tenure
49yo
Average Age
Experienced Management: ECX's management team is considered experienced (2.5 years average tenure).
Board Age and Tenure
4.9yrs
Average Tenure
70yo
Average Age
Experienced Board: ECX's board of directors are considered experienced (4.9 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Noel Doheny
Chief Executive Officer of Epigenomics Inc.
- Tenure: 8.4yrs
Jorge Garces (47yo)
President
- Tenure: 1.8yrs
- Compensation: €934.64k
Greg Hamilton (49yo)
CEO & Member of the Executive Board
- Tenure: 3.3yrs
- Compensation: €962.25k
Albert Weber (56yo)
Executive VP of Finance & Member of the Executive Board
- Tenure: 1.8yrs
- Compensation: €422.01k
Peter Vogt
Vice President of Corporate Communications & Investor Relations
- Tenure: 0yrs
Frederic Hilke
Investor Relations Officer
- Tenure: 0yrs
Board Members
Ann Kessler (75yo)
Deputy Chairwoman of the Supervisory Board
- Tenure: 7.4yrs
- Compensation: €52.00k
Günther Reiter
Vice-Chairman of the Supervisory Board
- Tenure: 4.9yrs
- Compensation: €52.00k
Heino von Prondzynski (70yo)
Chairman of the Supervisory Board
- Tenure: 7.4yrs
- Compensation: €102.00k
Helge Lubenow
Member of the Supervisory Board
- Tenure: 3.4yrs
- Compensation: €47.00k
Franz Walt (60yo)
Member of the Supervisory Board
- Tenure: 0.4yrs
Company Information
Epigenomics AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Epigenomics AG
- Ticker: ECX
- Exchange: XTRA
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €46.648m
- Shares outstanding: 36.02m
- Website: https://www.epigenomics.com
Number of Employees
Location
- Epigenomics AG
- Geneststrasse 5
- Berlin
- Berlin
- 10829
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EPGN.F | OTCPK (Pink Sheets LLC) | Common Shares | US | USD | Jul 2004 | |
| EPGN.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Jul 2013 | |
| ECX | DB (Deutsche Boerse AG) | Yes | Registered Shares | DE | EUR | Sep 2014 |
| ECX | XTRA (XETRA Trading Platform) | Yes | Registered Shares | DE | EUR | Sep 2014 |
| 0QXH | LSE (London Stock Exchange) | Yes | Registered Shares | GB | EUR | Sep 2014 |
| ECXD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Registered Shares | GB | EUR | Sep 2014 |
Biography
Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asi ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/18 21:21 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.